Financial Data and Key Metrics Changes - The company reported a profit of $26 million in the first half of 2024, with revenue from marketed products increasing by 64% at constant exchange rates to $128 million [9] - Consolidated oncology revenue reached $168 million, on track to meet the full-year revenue guidance of $300 million to $400 million [9][10] - R&D expenditures decreased to $95 million due to strategic reorganization and project prioritization [9] Business Line Data and Key Metrics Changes - Fruquintinib's U.S. market sales exceeded $130 million in the first half, indicating strong early uptake [7] - In China, all products experienced double-digit growth, contributing to a combined in-market sales growth of 145%, primarily driven by Fruquintinib U.S. sales [7] - The company is preparing for the launch of savolitinib in the U.S. later this year [6] Market Data and Key Metrics Changes - The U.S. market for Fruquintinib showed strong performance, with expectations for Japan and EU launches later in the year [11] - The competitive landscape in China remains challenging, yet the company maintains its market leadership in the third-line metastatic colorectal cancer (mCRC) segment [11] Company Strategy and Development Direction - The company is focused on globalization and self-sustainability, with plans to launch Fruquintinib worldwide in partnership with Takeda [6] - The pipeline includes multiple products under review, with a focus on life cycle indications for existing products and new product launches [7][14] - The company aims to achieve profitability potentially ahead of the previously set target of 2025 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the second half of 2024, highlighting numerous upcoming events that could fuel growth [23] - The company is actively preparing for market launches and is optimistic about the regulatory approval processes for its products [34][38] Other Important Information - The company maintains a strong cash position of over $800 million, allowing for continued investment in R&D and commercial operations [10][64] - The company is engaged in ongoing business development discussions and is focused on clinical development globally [34] Q&A Session Summary Question: Insights on SAVANNAH data and U.S. submission leadership - Management confirmed that AstraZeneca is leading the trial and NDA submission, with the company contributing to the package [26][28] Question: Sales guidance for Fruquintinib and EU strategy - Management indicated that there are no updates on sales guidance from Takeda, but they expect a launch in Europe before the end of the year [33][34] Question: Regulatory approval status for second-line gastric cancer - The NDA review is ongoing, with an anticipated decision in Q3 2024 [38] Question: Feedback on Fruquintinib's U.S. sales and patient demographics - Management noted that they do not have clarity on patient demographics but emphasized the drug's unique pharmacological profile [56] Question: R&D expenditure outlook for the second half of the year - Management expects R&D investment to increase in the second half, although it will still be less than the previous year [48] Question: Exploration of additional indications for Tazemetostat - Management confirmed ongoing studies for Tazemetostat in second-line follicular lymphoma and other potential solid tumors [50][53] Question: Use of surplus capital - Management plans to gradually increase investments in R&D and commercial operations rather than returning capital to shareholders [64]

ADVANCING TO GLOBAL LAUNCHES & CONTINUED PIPELINE PROGRESS H1 2024 RESULTS & BUSINESS UPDATES July 31, 2024 Nasdaq/AIM:HCM | HKEX:13 looop HUTCHMED Safe harbor statement & disclaimer The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation R ...

Exhibit 99.1 HUTCHMED Reports 2024 Interim Results and Provides Business Updates Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 31, 2024: HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Pu ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 收入增長勢頭持續，現金結餘充裕支持擴展 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 呋喹替尼全球佈局持續推進，管線進一步拓寬並取得切實進展 （於開曼群島註冊成立的有限公司） 1 / 70 （股份代號：13） 和黃醫藥公佈2024年中期業績及最新業務進展 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」、「本公司」或「我們」）今日公佈截至2024年6月30日止六個月的 財務業績以及提供關鍵臨床項目和商業化發展的最新進展。 公司將於今天中國香港時間晚上8時/英國夏令時間下午1時/美國東部夏令時間上午8時舉行網絡直播（英語場 次），並於2024年8月1日（星期四）中國香港時間上午8時30分舉行中文（普通話）場次。投資者登記後可透過 和黃醫藥網站（www.hutch-med.com/event）參與實時網絡直播。 除另有說明外，所有金額均以美元列示。 • 重申2024年全年腫瘤/免疫業務 ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:​HCM; HKEX:​13) today reports its financial results for the six months ended June 30, 2024 and provides updates on key clinical and commercial developments. HUTCHMED to host results webcasts today at 8:00 a.m. EDT / 1:00 p.m. BST / 8:00 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, August 1, 2024. After registration, investo ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English co ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. The English co ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During the event, the senior management team will share insights into the Company's R&D strategy and vision. Additionally, the team will provide updates on certain programs within HUTCHMED's extensive and innovative pipeline. This will include updates on the ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During the event, the senior management team will share insights into the Company’s R&D strategy and vision. Additionally, the team will provide updates on certain programs within HUTCHMED’s extensive and innovative pipeline. This will include updates on the ...

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (NYSE:TAK) has received notification from th ...